Novo Nordisk appoints Dilek Dogan Gurluk as new head of Irish business
Wegovy maker’s top investor proposes international board overhaul
Novo Nordisk
Trump’s bully boy tactics bringing Big Pharma to heel
Determination to cut prices for medicines in US may yet pile pressure on creaking European health budgets
‘Obesity medications may not make you thin or happy but they will improve your health’
GLP-1 drugs need to be reframed in the public mind as an essential medical treatment rather than ‘skinny jabs’, say practitioners
Irish stocks outperform on budget day
Pan-European Stoxx 600 index fell 0.2 per cent as Novo Nordisk lost ground
Novo Nordisk to cut staff numbers at Irish business
Drugmaker notifies Government of collective redundancies
US says EU deal on pharma trade remains in place despite Trump threat
US president Donald Trump had earlier said he will impose 100 per cent import tariffs on pharma products
Novo versus Lilly spotlights wider Europe-US corporate divide
US firms usually look leaner than their European counterparts when judged by revenue per employee
Weight-loss drugmaker Novo Nordisk to cut 9,000 jobs amid increased competition
The company’s shares have nearly halved since the start of the year and expects slower growth this year
Novo Nordisk freezes hiring in push to rein in costs
Halt to hiring will apply across all markets and departments
Eli Lilly’s weight-loss breakthroughs face brutal investor scrutiny
Perfection was priced in, anything less provoked panic as shares were hit with worst one-day drop in 25 years
Eli Lilly obesity pill disappoints in trial, sending shares down 14%
Weight loss comes in at lower end of expectations and triggers stock boost for rival Novo Nordisk
‘A slow-moving car crash’: Novo Nordisk’s troubles keep mounting
Novo Nordisk has now lost two-thirds of its value in little over a year
Trump tariff letters unnerve investors with banks worst hit as markets drop
Pharma companies also volatile in wake of letters from US president to 17 of them demanding lower prices
In Ozempic’s home town they fear two things: a new set of tariffs, and a company in Kinsale
Pharmaceutical giants in Europe brace themselves for a tariffs fight that is likely still to come
Global stocks fluctuate as oil erases rally
Aviation stocks drop amid soaring jet fuel prices in Europe
Global markets mixed ahead of key central bank meetings
Iseq index advances 0.5%, dragged higher by Ryanair and the main Irish banks
Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
Parvus shows interest in Danish drugmaker that is hunting for new chief following share price slump
Should the maker of Ozempic be funding children’s playgrounds in Ireland?
In 2023, Novo Nordisk was suspended by its own industry body in the UK for two years over its sponsorship of weight management courses for health professionals
Maker of Ozempic and Wegovy broke advertising rules, regulator finds
‘Significant number of non-compliances’ by pharmaceutical firm behind weight loss drugs
Ousted Novo Nordisk CEO pays for investors’ inflated hopes
Investor expectations, it seems, are harder to manage than blood sugar
Ireland U-turns to oppose EU pharma reforms after intense lobbying
Pharmaceutical companies stepped up blitz to push Government to back industry position, lobbying logs show
Novo Nordisk ousts boss as Ozempic maker battles profit slump
Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed
Novo Nordisk cuts sales forecasts on lower US demand for obesity drug
First-quarter sales rise 18 per cent but Danish pharma group blames custom preparations at pharmacies for weaker take-up
Novo Nordisk on the back foot ahead of earnings
Drugmaker has seen shares halved as obesity market heats up
Big pharma sees positive side effects in Trump tariffs
Industry has used trade opportunity to hand European Commission a shopping list of asks
Lilly’s weight loss pill is a ‘landmark moment’ in the obesity fight
Prof Donal O’Shea hails breakthrough and says it may play key role in reshaping treatments
Trillion-euro dream fades for slimmed-down Novo Nordisk
SAP is now Europe’s most valuable public company
Weight loss drug Wegovy to cost around €220 a month as supplies go on market in Ireland
Weight loss drug is not yet approved for reimbursement under Drug Payment Scheme or for medical card patients
Wegovy: The obesity ‘wonderdrug’ comes to Ireland, but it will cost you
Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now at least
Pharma firms ‘disappointed and concerned’ by lack of State support for campaign against EU reforms
New regulations of pharma sector could cost jobs in Ireland, industry warned Government
Inside the pharma industry’s lobbying campaign to water down reforms
Pharma companies ‘disappointed’ in Government’s stance during EU negotiations
Generic drugmaker races to launch versions of blockbuster obesity drugs
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year
Novo Nordisk to explore how obesity drugs can help patients with addiction
Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
The GlossOpens in new window
Read the digital edition of The Gloss magazine now
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices